Subgenomic SARS-CoV-2 replicon and reporter replicon cell lines enable ultrahigh throughput antiviral screening and mechanistic studies with antivirals, viral mutations or host factors that affect COVID-19 replication

Shuiyun Lan¹, Philip R. Tedbury¹, Yee Tsuey Ong¹, Raven Shah¹, Ryan L. Slack¹, Maria E. Cilento¹, Huanchun Zhang¹, Haijuan Du¹, Nicole Lulkin¹, Uyen Le¹, Karen A. Kirby¹, Ivo Melcak¹, William A. Cantara¹, Emerson A. Boggs¹, and Stefan G. Sarafianos^{1,2,*}

¹ Division of Laboratory of Biochemical Pharmacology, Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA; ²Children's Healthcare of Atlanta, Atlanta, GA 30322, USA;

*corresponding author: stefanos.sarafianos@emory.edu

ABSTRACT

Replicon-based technologies were used to develop reagents and assays for advanced drug discovery efforts against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and for examining all facets of the SARS-CoV-2 replication cycle at reduced biocontainment level. Specifically: a) 21 replicons were cloned in bacterial artificial chromosomes (BACs) and delivered as transfectable plasmid DNA or transcribed RNA in various cell types. Replicons carrying mutations that affect the activity or antiviral susceptibility of SARS-CoV-2 enzymes were used to establish utility for mechanistic studies while reducing the community risks associated with gain-of-function studies in fully infectious virus. b) A BHK-21 stable cell line harboring SARS-CoV-2 replicon was generated and characterized in robust high/ultra-high throughput assays of antiviral efficacy with orthogonal SARS-CoV-2 replication reporter genes (Nano luciferase and enhanced green fluorescent protein-eGFP); the estimated antiviral potencies in the fully infectious SARS-CoV-2 system and in the transient or stable replicon systems were similar. HEK293 and Calu1 stable cell lines expressing SARS-CoV-2 replicon have also been prepared. Finally, c) we generated trans-encapsidated replicons by co-expression with SARS-CoV-2 structural proteins, thus producing single-round infectious SARS-CoV-2 virus-like particles that are able to transduce susceptible cell types and have expanded utility to enable study of virion assembly and entry into target cells. Hence, these SARS-CoV-2 replicon-based reagents include a novel approach to replicon-harboring cell line generation and are valuable tools that can be used at lower biosafety level (BSL2) for drug discovery efforts, characterization of SARS-CoV-2 and variant evolution in the COVID-19 pandemic, mechanisms of inhibition and resistance, and studies on the role of SARS-CoV-2 genes and host dependency factors.

INTRODUCTION

As of the end of 2021, we are at the peak of the global COVID-19 pandemic, a respiratory disease with more than 280 million confirmed cases (record-high single-day infections on 12/23/2021 of 982,000 cases) and over 5.4 million fatalities around the world (1). The causative agent of COVID-19 (2, 3) is Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), an enveloped, positive-sense, single-stranded RNA betacoronavirus of the order Nidovirales, family Coronaviridae. Prior to SARS-CoV-2, illness caused by endemic coronaviruses (4), and the outbreaks of the original SARS-CoV in 2002 (5-7) and Middle-East Respiratory Syndrome CoV (MERS-CoV) in 2012 (8) (9), highlight the threat coronaviruses pose to human health.

The vaccines currently in use for the prevention of SARS-CoV-2 infection (10, 11) have proven to be effective at reducing the hospitalization and mortality from COVID-19, and are likely to continue to be a major part of the response to this and future outbreaks. However, vaccination strategies face multiple challenges, including the limited global vaccine supply, the difficulty in achieving the theoretical herd-immunity threshold at current vaccination rates, the reported waning of immunity against the virus a few months after vaccination, and the emergence of SARS-CoV-2 variants that spread very efficiently and are extensively mutated at the Spike surface glycoprotein, which has been the main target for vaccine development (12, 13) (14-16). Therefore, effective antivirals that target viral proteins less likely to mutate will be an critical component of the global response to coronaviral outbreaks.

The nucleoside analogue remdesivir (RDV) was the first SARS-CoV-2-targeting antiviral approved by FDA for treatment of COVID-19 patients requiring hospitalization (reviewed in (17)). However, it can only be injected at a hospital setting and its efficacy has been questioned (18, 19). Recently, another nucleoside analog was approved: molnupiravir (EIDD-2801 or MK-4482), which is the orally available pro-drug of the β -d-N4-hydroxycytidine (20). Molnupiravir reduces hospitalization or death by 30% (21, 22). Viral proteases have also been excellent targets for the development of antiviral drugs (23, 24). Several have been reported to have activity *in vitro* or are in clinical trials (25-28), and one formulation, Paxlovid (nirmatrelvir with ritonavir) (29, 30), was recently approved for use in the USA (31). Paxlovid was reported to reduce the risk of hospitalization or death by 89% in non-hospitalized high-risk adults (clinical trial NCT04960202) (32). These major targets, and several other enzymatic activities are essential to replicon activity, allowing replicons to be used for initial screening for drug discovery, and characterization of mechanism of action and potential mechanisms drug of resistance, following mutation of the viral genome.

There is clearly a need for discovery and development of novel drugs that target SARS-CoV-2 replication. The virus is readily cultured and infectious clones have been produced with reporter viruses to facilitate such studies (33, 34). However, a challenge for such studies is the requirement of handling infectious SARS-CoV-2 in biosafety level-3 (BSL3) facilities, which limits the number of academic and pharmaceutical laboratories able to contribute to the search for effective therapeutics. Subgenomic replicon systems provide biologically safe models that recapitulate a large part of the viral replication cycle and can play a major role in the discovery and development of antivirals, in addition to providing an invaluable tool for basic research into viral replication (35-37).

The general strategy of producing subgenomic replicons involves removing the structural protein coding sequences and replacing them with reporters and/or selectable markers, while retaining all proteins and any nucleic acid sequences required for genome replication. The genomic RNA (gRNA) of coronaviruses is flanked by 5' and 3' untranslated regions (UTR); the first two thirds of the genome codes for the non-structural proteins (nsp) in the form of ORF1a and ORF1b polyproteins (reviewed in (38, 39)), the final third codes for the structural proteins (spike S, Envelope E, Membrane M, and Nucleocapsid N), as well as several putative ORFs for accessory factors (9) (**Figure 1A**). The genome has a 5' cap and 3' polyA tail and serves initially as the template for translation of ORF1a and ORF1b, into the pp1a and pp1b polyprotein precursors that are processed by the viral proteases nsp3 and nsp5 to release 16 mature proteins (nsp1-16, key functions listed in **Figure 1A**) including all predicted components of the replication-transcription complex (RTC). The RTC produces negative strand (-) genomic and subgenomic (sg) RNAs from the genomic RNA. The generation of (-) sgRNAs is regulated by the transcriptional regulatory sequences (TRS). During the synthesis of the (-) RNA, the body TRSs (TRS-B) that precede each ORF (**Figure 1A**) act as potential dissociation signals for the RTC leading to a strand transfer to the TRS leader region of the 5'-UTR (TRS-L), to resume the synthesis of (-) sgRNA. The (-) RNAs are used as templates to synthesize full-length genomic RNAs and a nested set of sgRNAs. The frequency with which each TRS-B triggers dissociation during (-) RNA synthesis determines the relative abundance of each sgRNA and genomic RNA, such that the genomic RNA is relatively scarce while some sgRNAs, and consequently the proteins they code, are highly abundant (39).

A variety of SARS-CoV-2 replicon systems have been published to date, featuring a range of advantages and disadvantages. Most involve the production of an RNA carrying one or more reporters and can be introduced into permissive cells by electroporation (24, 40-45). Some additionally have

demonstrated the capability to be trans-encapsidated by co-expression with the deleted structural elements to produce single round infectious particles (41, 43, 45, 46).

Here, we report the generation of more than 20 SARS-CoV-2 replicons, including constructs containing orthogonal reporter proteins and selectable markers. The replicons are based on the “parental” Washington isolate (WA) as well as several Variants of Concern (VOC) and Variants Being Monitored (VBM). We validate the replication dependence of reporter gene expression by use of replication-inactive mutants and well characterized inhibitors of viral enzymes, and thus the utility of these replicons for characterization of antiviral agents. We show that these subgenomic replicons can be delivered as plasmid DNA or transcribed RNA; we also show that the replicons can be trans-encapsidated by co-expression with SARS-CoV-2 structural proteins to produce virus-like particles (VLPs) capable of transducing angiotensin converting enzyme 2 (ACE2)-expressing cells (when bearing the SARS-CoV-2 S protein) or non-ACE2-expressing cells (when bearing the vesicular stomatitis virus glycoprotein). Importantly, we were able to generate stable cell lines harboring the SARS-CoV-2 replicon, a potentially valuable resource to facilitate identification and characterization of novel antivirals.

RESULTS

Construction of SARS-CoV-2 replicons (SARS-2Rs)

To facilitate the cloning of such large constructs, replicons were engineered in a bacterial artificial chromosomes (BAC) through stepwise cloning of DNA fragments (synthetic or prepared by RT-PCR from the SARS-CoV-2 Washington isolate, WA) into the BAC, exploiting unique restriction sites (**Figure 1B**). Many replicons have employed T7 promoters to permit *in vitro* transcription of replicon RNA, to be introduced into cells by electroporation (24, 40-45). To remove the necessity of generating RNA, an alternative approach employs a 5' cytomegalovirus (CMV) promoter to drive initial transcription of replicon RNA (46-50). We built a replicon with a T7 promoter and a 3' hepatitis delta virus ribozyme to ensure generation of the correct 3' terminus. The base design incorporated the viral sequences essential for genome replication: the 5' and 3' UTRs, ORF1a and ORF1b, and N with its TRS-B. Reporters [Nano luciferase (NLuc) or NLuc with eGFP] and selectable markers (puromycin-N-acetyltransferase – Puro^R or neomycin phosphotransferase – Neo^R) were inserted in place of M, E, S and most of the accessory ORFs, following the TRS-B sequences for M or S (TRS-M or -S) to permit transcription of the sgRNA. Placement of the reporter cassette in a sgRNA ensures that these genes will be expressed at a high level, but only following transcription by the SARS-CoV-2 RTC. This replicon produced a high luciferase signal that could

be inhibited by RDV, indicating that the vast majority of reporter gene expression is generated by SARS-CoV-2 replication (**Figure S1**). However, to reduce labor and potentially increase reproducibility between constructs, we generated a second generation of replicon, replacing the T7 promoter with CMV promoter. After transfection of the BAC into target cells, transcription of full-length RNA is driven by the CMV promoter, allowing translation of ORF1a and ORF1b and formation of SARS-COV-2 RTC (**Figure 1**). The RTC then produces new gRNA and sgRNAs, *via* (-) RNA intermediates, leading to expression of the reporter genes and selectable markers. The BAC platform provides a stable platform for the generation of these large constructs; the introduction of unique restriction sites allows for modification of the reporter gene cassette or introduction of mutations into the replicon sequence through replacement of individual fragments. A partial list of replicons generated is shown in **Supplemental Table I**.

Figure 1. Genome organization of infectious SARS-CoV-2 and cloning strategy for the construction of the SARS-CoV-2 subgenomic replicon (SARS-2R). **A.** Genome structure of SARS-CoV-2 and open reading frames (ORF). L, is the leader sequence. Some non-structural proteins, nsp, and their functions are: nsp3, contains PLPpro, papain-like protease; nsp5, 3CLpro protease; nsp12, RNA-dependent RNA polymerase or RdRp; nsp13, helicase; nsp14, ExoN, exonuclease; nsp15, EndoU, endonuclease; nsp16, MTase, methyltransferase. PLPpro-, and 3CLpro-cleavage sites are depicted as black or white triangles, respectively. TRSs are transcription-regulatory sequences located immediately adjacent to ORFs; TRSs contain a conserved 6–7 nt core sequence (CS) surrounded by variable sequences. During negative-strand synthesis, nsp12 pauses when it crosses a TRS in the body (TRS-B) and switches the template to the TRS in the leader (TRS-L); UTR, untranslated regions. Select mutations in various replicons are shown: F480L/V557L, blue-RDV-resistance mutations; D618A/D760A, red-nsp12 active site; K345A/K347A, brown-nsp13 nucleic acid binding; D374A/E375A, nsp13 active site; D90A/E92A light brown nsp14 active site; H234A, purple-nsp15 active site; E203A green-nsp16 active site. **B.** General strategy for the construction of SARS-CoV-2 replicons. Multi-step cloning strategy was used, whereby the fragments named SARS-CoV-2/F1 to SARS-CoV-2/F9 were sequentially cloned into pBeloBAC11 vector to generate pBAC-SARS-CoV-2-REP. The genetic structure of the replicon and the position of relevant restriction enzyme sites are shown at the ends of each fragment. F9 contains the reporter cassette. Early SARS-2R versions included T7 promoter (downstream from the CMV promoter) and were used for *in vitro* transcription of replicon RNA.

Validation of replicon system in cell lines

To determine the optimal conditions for using nanoluciferase-producing SARS-CoV-2 replicon (SARS-2R_NL) we measured secreted NLuc over time in a range of cell lines (**Figure 2**). To differentiate between NLuc produced from the CMV promoter and replication-dependent NLuc expression, we used SARS-2R_NL with inactive nsp12 polymerase (nsp12_{D618A/D760}). In all cases, nsp12_{D618A/D760} samples exhibited >99% decrease in NLuc activity, demonstrating that reporter gene expression is overwhelmingly replication dependent. We found maximum NLuc signal in 293T, BHK-21 and CHO-K1 cells, while the greatest signal-to-noise (WT $\geq 10,000$ -fold greater than nsp12_{D618A/D760}) was achieved in BHK-21 and Caco2. As expected, mock controls (no SARS-2R_NL) produced no NLuc activity, while a robust signal for SARS-2R_NL WT over nsp12_{D618A/D760} was observed in all cell lines (**Figure 2**). In most cell lines, NLuc activity is measurable by 8 hours post transfection (hpt), with the signal typically plateauing 48 hpt. The differences in NL activity following SARS-2R_NL transfection among the various cell lines are likely dependent on a combination of transfection efficiency and differences in replication permissivity. These data demonstrate that protein expression from sgRNAs is replication dependent, and the reporter gene assays can be performed with high signal-to-noise in a range of convenient and/or physiologically relevant cell types, making this a suitable system for the study of SARS-COV-2 replication or screening for replication inhibitors.

Figure 2. Time course of luciferase activity in various cell lines transfected with SARS-2Rs. A. NLuc activity kinetics for SARS-2R_NL replicons. Cells were seeded at 5×10^4 cells/well in 24-well plates, 24 h before transfection. Cells were transfected with either mock (no plasmid) or 0.25 μ g wild-type (WT) SARS-2R-NL or polymerase inactive SARS-2R-NL (nsp12_{D618A/D760A}) plasmid and 0.025 μ g N, ORF3b, ORF6 expression plasmids. NLuc was measured at the times indicated. **B.** Comparison of NLuc activity at 72 hpt. Average data from 2 independent experiments shown with standard deviation.

Validation of replicase enzyme dependency of reporter gene expression

To determine whether SARS-2R replicons can be used to study the role of individual viral proteins and viral mutations in the replication mechanism of SARS-CoV-2 we constructed SARS-2R_NL_Puro^R replicons with mutations at various nsp active sites. Mutations at the predicted active sites of nsp12 (polymerase), nsp13 (helicase), and nsp15 (endonuclease), significantly reduce the activity of replicon activity in BHK-21 cells (**Figure 3A**). In particular, the nsp12_{D618A/D760A} and nsp13_{D374A/E375A} mutations entirely suppressed replication (>99.9% loss of activity). Similarly, the nsp15_{H234A} mutation resulted in >95% loss of activity. Mutations that were predicted to affect the nucleic acid binding function of SARS-CoV-2 helicase (51) (nsp13_{K345A/K347A}) were also detrimental to replicon activity (>80% loss of activity). Interestingly, mutations at the exonuclease active site of nsp14 (nsp14_{D90A/E92A}) and 2'-O-methyltransferase active site of nsp16 (nsp16_{E203A}) only induced partial loss of replication (approximately 50% in each case), indicating that these enzymes/functions are less critical to replication, or that under these conditions the mutations may not cause a complete loss of activity.

Figure 3. Fitness of SARS-2R-NLuc-Puro^R replicons bearing nsp mutations. Cells were transfected in 24-well plates with 0.25 µg of SARS-2R, together with 0.025 µg each of N-, ORF3b-, and ORF6- expression plasmids. Luciferase activity was measured at 48 hpt. **A.** Replicons carrying the indicated mutations were transfected into BHK-21 cells. **B.** Replicons that were either WT, ExoN(-) (nsp14_{D90A/E92A}) or RdRp(-) nsp12_{D618A/D760A} were transfected into the indicated cell lines. Averaged data from 2 independent experiments are shown with standard deviations.

The nsp14 ExoN(-) mutant result was probed in more detail, as ExoN(-) mutations in nsp14 have been reported to impart variable replication defects in different betacoronaviruses, ranging from a moderate decrease in activity of the embecovirus Mouse Hepatitis Virus (MHV) (52) and sarbecovirus SARS-CoV (53) to essentially non-viable phenotype in merbecovirus MERS-CoV and the latest sarbecovirus SARS-CoV-2 (54). As more dramatic loss of replication fitness has been reported in nsp14 ExoN(-) mutant SARS-CoV-2 than we initially observed (54), we repeated our analysis of these mutants in a range of cells and consistently observed a moderate reduction in replicon activity (typically 50-75%); Calu3 cells exhibited a more profound reduction (~98%) in activity with the ExoN(-) mutant replicon, however, replicon activity was lower generally in this cell line, potentially due to reduced transfection efficiency (**Figure 3B**). These data provide further validation of the replication-dependence of reporter gene expression, and indicate that this system would be particularly useful for studies of the polymerase and helicase, including screening for and characterization of small molecule inhibitors.

Use of SARS-2Rs in studies of Variants of Concern (VOC) and Variants Being Monitored (VBM).

One of the major concerns during the COVID-19 pandemic has been the emergence of variants that exhibit properties such as faster spread, immune escape, and potentially increased pathogenicity. Although many studies have focused on the role of the S protein, there is increasing evidence that other mutations throughout the genome contribute to the phenotypic differences between variants. Additionally, mutations in the RTC enzymes have the potential to affect susceptibility to current and future therapeutics.

We generated SARS-2R_NG_Neo^R_NL constructs derived from parental (WA), the alpha VBM B.1.1.7 (also known as “UK strain”), the beta VBM B.1.351 (also known as “South African or SA”), and the delta VOC B.1.617.2 (delta) viruses. Of note, the classification of SARS-CoV-2 variants as “of concern”, “of interest”, or “being monitored” has evolved during the course of the pandemic but the above variants have been thus classified by CDC as of 12/20/21. The VOC replicons differ from WA in ORF1a, ORF1b, N, and in non-coding regions (**Supplemental Table I**). To gain insight into whether the amino acid differences among variants in genes other than the S affect the replication efficiency of the B.1.1.7, B.1.351, and B.1.617.2 strains, we assessed replication in 293T cells (**Table I**). All replicons evinced clear replication above the polymerase-defective mutant WA replicon. However, the B.1.351- and B.1.1.7-

derived replicons showed measurably reduced replication relative to the WA-derived replicon, suggesting that the mutations in these strains may affect fitness in the 293T cell culture model.

We next compared the antiviral susceptibilities of the VOC replicons in 293T cells. We found no statistically significant difference between the potency of RDV, NHC, EIDD-2801, and GC-376 among the four replicons (**Table I**). To verify that this lack of change represented the biology of the virus, we compared the *replicon* values for WA and B.1.1.7 to the values obtained with same compounds in fully infectious WA and B.1.1.7 viruses; indeed, we did not find significant differences in antiviral potency for any of the compounds against the two strains (**Supplemental Table II**). These data demonstrate the similarity between virus and replicon in terms of drug resistance, and that these constructs represent a valuable resource for comparative studies of drug susceptibility of the major variants.

TABLE I. Effect of Variants Being Monitored (VBM) and Variants of Concern (VOC) replicon mutations on replicon fitness and antiviral efficiency in 293T cells

	Fitness (Fold change relative to WT)	Mean EC₅₀ ± SD (μM) (Fold change relative to WT)			
Replicon	NLuc activity (RLU)	RDV	NHC	EIDD-2801	GC-376
SARS-2R_NG_Neo^R_NL (WT or WA-derived)	2.7E+07 ± 8.3E+06 (1.0)	0.004 ± 0.001 (1.0)	0.75 ± 0.11 (1.0)	4.92 ± 2.03 (1.0)	0.36 ± 0.08 (1.0)
SARS-2R_NG_Neo^R_NL B.1.1.7 (Alpha - VBM)	1.0E+07 ± 5.2E+06 (0.4)	0.004 ± 0.001 (1.0)	0.88 ± 0.16 (1.2)	7.26 ± 1.49 (1.5)	0.33 ± 0.03 (0.9)
SARS-2R_NG_Neo^R_NL B.1.351 (Beta - VBM)	7.2E+06 ± 2.6E+06 (0.3)	0.005 ± 0.001 (1.3)	0.98 ± 0.10 (1.3)	6.62 ± 0.80 (0.7)	0.34 ± 0.03 (0.9)
SARS-2R_NG_Neo^R_NL B.1.617.2 (Delta - VOC)	8.7E+07 ± 3.6E+07 (3.2)*	0.008 ± 0.001 (2.0)*	1.10 ± 0.05 (1.5)	6.08 ± 0.62 (1.2)	0.39 ± 0.07 (1.1)

For all values N ≥ 2. Adjusted P Values in two-way ANOVA test comparing: Fitness of WT vs. Delta: 0.048; Alpha vs. Delta: 0.007; Beta vs. Delta: 0.007.

Use of SARS-R2 in high-throughput assays

Initial experiments with SARS-CoV-2 replicons were conducted in 24-well plates. To provide evidence for the utility of SARS-2R as a tool for drug discovery efforts we explored conditions for its use in high throughput multi-well plate formats. We showed that reproducible measurements of RDV inhibition can be carried out in a 384-well format, at a range of cell seeding densities using 293T cells, without significant differences in the estimated EC₅₀ and EC₉₀s (**Table II** and **Figure S2**). Of note, these data demonstrate that the assay is reliable even at 1,000 cells/well, which is well within the range of an ultrahigh throughput format in 1536-well plates. Assay miniaturization is underway. These values are comparable to published data using infectious virus (20). The variation in RDV potency between cell types has been observed previously and likely reflects efficiency of conversion of RDV nucleotide to RDV-triphosphate (55, 56). Finally, to quantify the robustness of the assay, we calculated the Z', comparing DMSO treatment to RDV; the average Z' and 95 % CI was 0.70 ± 0.032. These data support the robustness and reproducibility of the replicon-based assay, and its suitability to high-throughput applications.

Table II. Inhibition of SARS-2R_NL_Puro^R by remdesivir based on dose response assays in a 384-well format using 293T cells

Cells/well	EC ₅₀ (μM)	EC ₉₀ (μM)
16,000	0.004± 0.001	0.028± 0.004
8,000	0.004± 0.001	0.018± 0.011
4,000	0.004± 0.001	0.011± 0.002
2,000	0.003± 0.001	0.013± 0.007
1,000	0.004± 0.002	0.012± 0.002

N = 2, standard deviation indicated.

TABLE III. Inhibition of wild-type, RDV-resistant (nsp12_{F480L/V557L}) and exonuclease inactive (nsp14_{D90A/E92A}) SARS-2R_NL_Puro^R replicons by antivirals in 293T cells

Compound	EC ₅₀ (μM) ± SD		
	WT	nsp12 _{F480L/V557L} (fold change from WT)	nsp14 _{D90A/E92A} (fold change from WT)
RDV	0.003 ± 0.001	0.010 ± 0.005 (3.3)*	0.003 ± 0.001 (1.0)
NHC	0.76 ± 0.12	0.62 ± 0.18 (1.0)	0.73 ± 0.23 (1.0)
EIDD-2801	4.6 ± 2.4	4.5 ± 1.4 (1.0)	5.0 ± 0.92 (0.9)
GC-376	0.38 ± 0.08	0.30 ± 0.04 (1.3)	0.11 ± 0.02 (3.5)*

N=2, standard deviation indicated. Statistical significance indicated with *. RDV, remdesivir; NHC, β-d-N4-hydroxycytidine; EIDD-2801, molnupiravir.

We next used high throughput conditions with SARS-2R_NL_Puro^R to determine the potency of several antivirals with well-characterized activity against SARS-CoV-2 in 293T cells (**Table III**). Consistent with data reported for fully infectious SARS-CoV-2, the replicon was inhibited by RDV with an EC₅₀ of 0.003 μM, EIDD-2801 with an EC₅₀ of 4.67 μM, NHC with an EC₅₀ of 0.76 μM, and by the nsp5 inhibitor GC-376 with an EC₅₀ of 0.38 μM. We observed modest, but statistically significant (p<0.001) decrease in RDV susceptibility (3.3-fold), when comparing SARS-2R_NL_Puro^R WT to the replicon bearing the RDV resistance-associated mutations (nsp12_{F480L/V557L}) (**Table III**) analogous to the modest resistance previously reported in MHV (nsp12_{F476L/V553L}) and SARS-CoV (nsp12_{F480L/V557L}) (up to 5.6-fold) (57). A decrease in RDV susceptibility was observed when these replicons were tested in BHK-21 cells, however, it was not found to be statistically significant under the testing conditions (not shown). The RDV-resistant replicon appears to retain susceptibility to NHC, EIDD-2801, and GC-376.

It is also of interest to understand whether inhibition by various antivirals that target nsp12 and are incorporated in the elongating RNA chain can be affected by the ExoN activity of nsp14. In MHV, the ExoN(-) mutant had increased sensitivity to RDV (57). Hence, we also tested the potency of such antivirals using the SARS-2R_NL_Puro^R nsp14_{D90A/E92A} replicon that lacks ExoN activity. We found that genetic suppression of this activity did not significantly affect the EC₅₀ of NHC or EIDD-2801. Moreover, we did not observe any significant effect of the ExoN(-) mutations on RDV susceptibility (**Table III**); previously,

Agostini et al. reported a 4.5-fold increase in sensitivity of the corresponding mutant MHV compared to the WT virus (57). Surprisingly, we did find a statistically significant increase in GC-376 susceptibility of SARS-2R_NL_Puro^R nsp14_{D90A/E92A} compared to WT (two-way ANOVA p-value 0.003). We are currently investigating whether (and how) the mutations that suppress the ExoN function of nsp14 affect the function of nsp5 and its interactions with GC-376.

In addition to resistance to an antiviral agent, the potential risk associated with drug-resistance mutations depends on their fitness. We used the replicon system to examine the effects of RDV-resistance associated mutations on fitness. Consistent with the reported modest decrease in production of infectious virus (57) our data show that the nsp12_{F480L/V557L} mutations reduce the replicon activity by ~20 % (**Figure S3**). Interestingly, the nsp12_{F480L/V557L} mutations in the background of ExoN(-) nsp14 (nsp12_{F480L/V557L}, nsp14_{D90A/E92A}) seemed to significantly suppress replicon activity by 98%, far more than either pair of mutations alone. Collectively, these data illustrate the value of replicons for exploring the potential impacts of drug-resistance associated mutations on SARS-CoV-2 replication.

Generation of SARS-CoV-2 replicon-expressing cell lines

While the use of replicon DNA to transfect BHK-21 cells streamlines the workflow relative to the use of transcribed RNA, the workflow can be simplified further through the use stable replicon harboring cell lines; similar tools have proven extremely beneficial in drug development for HCV (58, 59). Surprisingly, while a stable replicon harboring cell line was generated for SARS-CoV (60), none of the published SARS-CoV-2 replicon systems have led to the production of stable replicon harboring cell lines. We generated stable cells by transfecting BHK-21 cells with replicon DNA and then applying neomycin selection. GFP fluorescence and NLuc activity were monitored over time to confirm the presence of actively replicating replicons. After 4 weeks selection with neomycin clonal cell lines were selected and we identified one, BHK-SARS-2R_GFP_Neo^R_NL, which exhibited GFP fluorescence and generated robust NLuc signal that persisted for multiple passages under selection and could be suppressed by treatment with RDV (>95%), indicating selection of a cell line with SARS-CoV-2 replication dependent reporter gene expression (**Figure 4**). Thus, this cell line can be used for multiplex assays that concomitantly follow NLuc and fluorescent signals, allowing for following highly sensitive and live replicon signal. There was no observable cytotoxicity due to the replicon and the cell morphology was typical of BHK-21 cells.

The generation of a replicon stable cell line in which on a small percentage of cells exhibit evidence of active replicon gene expression is atypical and prompted further characterization. We

performed qPCR and RT-qPCR to determine the levels of replicon RNA and plasmid DNA present in the cell line. After several weeks of passaging following transfection, we expected to find no replicon plasmid DNA, however, we found an estimated 1.2 (± 0.9) replicon DNA copies per cell. We also found 35 (± 26) replicon genomic RNA copies per cell. These data suggest that most/all of the cells carry an integrated copy of the plasmid, but at any given time only a small percentage of those cells contain active replicons.

Figure 4. BHK-21 stable cell line of SARS-2 replicon. SARS-2R_GFP_NeoR_NL was transfected into BHK-21 cells in a 6-well plate. Cells were transferred to 10-cm dish 24 h post transfection and treated with 1 mg/ml G418 from 48 hpt. Colonies were picked and cultured under selection. A. Following establishment of a stable cell line GFP expression was monitored over time. B. NLuc activity was assayed 48 h following treatment with RDV.

Table IV. Phenotypic stability of the BHK-SARS-2R_GFP_Neo^R_NL replicon harboring cell line following sorting into homogeneous populations

Sorted population	% GFP positive cells			
	0 h	24 h	48 h	168 h
GFP+	100 $\pm$ 0.0	12.7 $\pm$ 2.8	4.5 $\pm$ 1.3	0.95 $\pm$ 0.44
GFP-	0.0 $\pm$ 0.0	0.11 $\pm$ 0.03	0.43 $\pm$ 0.13	0.30 $\pm$ 0.05

N=2, standard deviation indicated.

To determine whether replicon activity was a stable phenotype, we separated the population of cells harboring active replicons (marked by GFP expression) from the overall population using fluorescence-activated cell sorting and acquired two populations of cells: GFP-positive (replicon active) and GFP-negative (replicon inactive). The phenotypes were confirmed by high content imaging and the cells cultured separately. The GFP-positive population rapidly declined from 100% to <5% of cells GFP positive after 48 h. Similarly, the proportion of GFP-positive cells in the GFP-negative sorted population climbed from 0% to almost 0.5% in 48 h (**Table IV**). After a week, the original phenotype of <5% GFP-positive (active replicon) was observed in both sorted populations, possibly because GFP-expression, and thus replicon activity, may not be a stable phenotype. The lack of replicon gene expression in most cells could be a consequence of inefficient transcription of the replicon RNA from the integrated DNA, or suppression of the replicon replication and gene expression by elements of the innate immune system. To better understand the replication characteristics of the BHK-SARS-2R_GFP_Neo^R_NL cell line, we imaged live cells over 48 h in the presence of sodium butyrate (a histone deacetylase inhibitor) to relieve putative repression of transcription, ruxolitinib (a Janus kinase inhibitor) to block induction of IFN-induced gene expression, and RDV to block replicon activity (**Figure 5A**, **Figure S4** and **Figure S5**). We found that sodium butyrate induced a 2-fold increase in GFP-positive cells relative to the untreated control, while ruxolitinib induced a strong 10-fold increase; treatment with both compounds was indistinguishable from ruxolitinib alone. Similar data were obtained using baricitinib, another JAK inhibitor (**Figure S6**). In all cases treatment with RDV prevented any increase in GFP-positive cells, confirming that the GFP-expression observed was dependent on the replicon RTC. Consistent with the hypothesis of unstable replicon replication, examination of the time-lapse images collected for the DMSO-treated BHK-SARS-2R_GFP_Neo^R_NL cells revealed examples of GFP-positive cells appearing where there were previously none (**Figure 5B** – red arrowheads), a phenotype that was markedly more pronounced in ruxolitinib treated cells. There were also examples where cells that previously expressed GFP disappeared (**Figure 5B** – red circles), consistent with the reversion of the GFP-positive sorted cells to a predominantly GFP-negative population. Collectively, these data indicate that the replicon coding plasmid is integrated into the cell genome but is unable to establish persistent replication, consequently at any given time only a small percentage of cells contain active replicon replication. The time-lapse imaging results, in particular enhanced replicon activity in the presence of JAK inhibitors, suggests that the replicon stochastically activates but may be suppressed by IFN-mediated innate immune responses.

Figure 5. SARS-CoV-2 replicon activity following inhibition of IFN-signaling and derepression of transcription. BHK-SARS-2R_GFP_Neo^R_NL cells were incubated with media containing the additives indicated. **A.** Replicon activity was assessed by counting GFP-positive cells. Images were collected at 4 h intervals using a high-content live-cell imaging system. **B.** Images of DMSO- and ruxolitinib-treated cells with time post-treatment indicated in hours. Cells with active replicon replication are GFP-positive. Solid red circles indicate active cells that disappear at later time points; dashed circles indicate the regions where the positive cells were. Solid red arrowheads indicate active cells that were not visible at earlier time points; empty red arrowheads indicate the same region prior to activation of the replicon. NaBtr, sodium butyrate; Ruxo, ruxolitinib; RDV, remdesivir. Representative data shown from one of two independent experiments.

Validation of replicon-harboring cell lines for small molecule discovery and characterization

A major application for such a stable cell line is to facilitate compound screening and characterization of hit compounds. To validate the use of the BHK-SARS-2R_GFP_Neo^R_NL cell line, we determined the EC₅₀ for RDV using both the NLuc and GFP markers (**Table V and Figure S7**). The EC₅₀ values determined using either reporter were generally comparable, both to one another and to values reported in the literature (2, 20, 27, 55). Of note, some differences in RDV potency have also been reported when tested in different cell lines, due to changes in its intracellular metabolism.

Table V. Determination of RDV efficacy using orthogonal reporter genes in the BHK-SARS-2R_GFP_Neo^R_NL cell line

	EC ₅₀ (μM) NLuc activity	EC ₅₀ (μM) GFP fluorescence
RDV	0.094 ± 0.001	0.082 ± 0.001
NHC	0.81 ± 0.18	0.88 ± 0.081
EIDD-2801	6.0 ± 1.5	6.4 ± 2.8
GC-376	0.29 ± 0.056	0.36 ± 0.042

N=2, standard deviation indicated.

Generation of SARS-CoV-2 replicon-carrying VLPs by trans-encapsidation with SARS-CoV-2 structural proteins

The replicon system provides an invaluable resource for the study of processes related to replication of RNA and protein expression, however, the absence of essential structural proteins makes it impossible to study the processes of particle assembly and release, and virus entry. To expand the utility of the replicon system to address these functions, while retaining the advantages of a BSL2 compatible system, we supplied the M, E and S in trans by co-transfecting structural protein expression vectors with the replicon plasmid SARS-2R_GFP_Neo^R_NL into 293T cells. After 48 h, media were collected and filtered, and used to transduce SARS-CoV-2 susceptible cell lines, either 293T-hAT or Huh7.5-hAT. After a further 48 h, reporter gene expression was measured as GFP-positive cells and NLuc activity in the media.

We were able to transduce both of the ACE2-expressing cell lines with VLPs bearing the SARS-CoV-2 spike protein (VLP_SARS2-S) or the SARS-CoV spike protein (VLP_SARS-S), but not with VLPs

lacking any envelope protein (VLP_Mock) (**Figure 6**). Comparing 293T cells (which do not endogenously express ACE2) to ACE2- and TMPRSS2-expressing 293T-hAT cells, we confirmed that both VLP_SARS2-S and VLP_SARS-S require ACE2 for successful transduction (**Figure 6A**). Similarly, comparing Huh7.5 cells to Huh7.5-hAT (Huh7.5 cells express ACE2; Huh7.5-hAT express additional ACE2 and TMPRSS2) revealed enhanced transduction with VLP_SARS2-S and VLP_SARS-S; by contrast VLP_VSV-G particles were able to transduce the target cells; similarly, transduction of ACE2-expressing cells by VLP_SARS-2R_GFP_Neo^R_NL_S was inhibited by a SARS-CoV-2 neutralizing monoclonal antibody. As a final control, we confirmed that reporter gene expression was dependent on replicon replication, following transduction, as all VLPs could be inhibited by treatment with RDV.

Figure 6. Trans-encapsidation of SARS-CoV-2 replicon. 293T cells were co-transfected with expression vectors for SARS-2R_GFP_Neo^R_NL, E, M and one of SARS-2 S, SARS S VSV-G or empty vector. After 48 h, VLP media were collected, filtered and used to transduce the cell lines indicated. NLuc activity was measured 48 h post transduction. **A.** Transduction of 293T and 293T-hAT with VLPs bearing SARS S or SARS-2 S. **B.** Transduction of Huh7.5 and Huh7.5-hAT with VLPs bearing SARS S, SARS-2 S or VSV-G. Prior to transduction, some cells were treated with RDV to inhibit replication, or an S-targeting neutralizing antibody (NAb) to prevent VLP entry. P values for pairwise comparisons determined by 2-way ANOVA: ****, $p \leq 0.0001$; *** $p \leq 0.001$. Means shown with standard deviation. N=3, except for “No VLP” and “VSV-G” where N=2.

DISCUSSION

Despite significant success in the fight against COVID-19, both in the development of effective vaccines and some small molecule therapeutics, SARS-CoV-2 has proven remarkably resistant to elimination efforts. The persistence of the global pandemic and the continuing evolution of the virus make it ever more important to expand research into both coronavirus biology and SARS-CoV-2 therapeutics specifically. A primary limitation in SARS-CoV-2 research is the high risk associated with working with a pathogenic respiratory pathogen, in terms of both the availability of suitable facilities and of suitably trained researchers. Here we present a range of approaches to facilitate research into all facets of SARS-CoV-2 replication, including cell entry, nucleic acid transcription and replication, and virus assembly and release; collectively these systems are tools to identify and characterize inhibitors at any point in SARS-CoV-2 replication. These systems are based on subgenomic SARS-CoV-2 replicons carrying reporter genes, reducing biological hazards and providing means to easily measure viral replication.

The most popular strategy for generating replicons from positive-strand RNA virus is to transcribe RNA *in vitro* that can be electroporated into target cells to initiate replication. To facilitate use of the assay, particularly in the context of large-scale screening, we eliminated the need for *in vitro* transcription by cloning cDNA for the SARS-CoV-2 replicons into a BAC under control of a CMV promoter. The replicon comprised all replication-essential proteins and sequences but omitted the structural proteins S, E, and M; additionally, reporter genes were included as a separate ORF using the TRS-B of M to drive production of the sgRNA expressing the reporter cassette. Placing the reporter cassette in a sgRNA ensured that formation of a functional RTC was essential for reporter gene expression. We validated the replication dependence using both genetic ablation of essential viral enzymes and the use of well characterized inhibitors of SARS-CoV-2 replication. Combining these controls with a screen of suitable cell lines, we were able to demonstrate replication-dependent reporter expression with signal-to-noise ratios between 1:100 and 1:>10,000; this wide dynamic range combined with an excellent z' score indicate that these replicons will be well suited to small molecule screening and should be able to resolve a wide range of magnitude of phenotypes associated with modulation of viral or cellular factors. Additionally, we built replicons based not only on the early WA1 isolate, but also more recent variants, including alpha VBM B.1.1.7, beta VBM B.1.351, delta VOC B.1.617.2, and epsilon VBM CAL.20C (characterization of epsilon and cloning of omicron are in progress). Liu et al. highlighted that from May 2 to July 31 of 2021, the prevalence of the delta variant in the USA increased (from ~1 % to 94 %), while that of the alpha variant decreased (from 70% to 2.4%) (61). They also showed that the delta P681R

mutation on S enhanced the cleavage of the full-length spike to S1 and S2, leading to increased infection *via* cell surface entry. The measurably increased replication of the delta replicon suggests that the increased transmissibility of the delta VOC may also be due in part to mutations at regions outside the Spike protein. This hypothesis is currently under investigation.

In addition to the dynamic range of the assay, a major concern when screening for small molecules inhibitors of viral replication is the potential of scoring inhibitors of the reporter gene as antiviral hits. To mitigate that risk, we have generated replicons with orthogonal reporter genes (NLuc and GFP), an approach successfully employed by others (40, 46, 50), and shown that measurements of antiviral potency are similar, whichever reporter is used.

In a final step to enhance the utility of these replicons for small molecule screening, we generated a BHK-21-based stable cell line harboring the dual-reporter replicon and showed that it can be used to determine the potency of antiviral compounds. Stable cell lines are of particular use for high throughput screening, to this end we demonstrated the utility of this stable cell line for high-throughput screening by determining the potency of RDV vs. SARS-CoV-2 in a 384-well plate format. The combination of orthogonal reporters, high sensitivity for use in 384-well plates, and the convenience of the stable cell line format, combined with the biological safety of a replicon (most robotic screening facilities are not located in BSL3 laboratories), make this system highly suitable for small molecule discovery and characterization efforts.

While not diminishing the utility of this stable cell line, it is worth noting that it differs from the majority of replicon-harboring cell lines, in that the host cells contain replicon-coding DNA integrated into their genome. While most replicon-harboring cell lines are based on self-replicating RNA expressing a selectable reporter (35, 60), this approach has proven challenging for SARS-CoV-2 as we and others have explicitly tried and failed to generate such cell lines. Possible explanations include potential suppression by IFN-mediated immune responses and/or killing of replicon-harboring cells by expression of viral proteins such as nsp1 (50, 62, 63). Indeed, a recent pre-print reports the generation of a mutant replicon-harboring cell line, with a mutation in nsp1 (64). These factors may contribute to the replicon quiescence we observed in the majority of cells and the lack of sustained reporter gene expression following initiation of replication. Significantly, when the cell line was sorted for homogeneous populations of reporter gene expressing or non-expressing cells, we found that both rapidly reverted to the pre-sorted proportion of cells harboring active replication. This suggests that the cells in the cell line may be continuously initiating transient replication but failing to sustain replicon replication. It may also

be relevant that the cell line could be established with G418 selection but not puromycin. If cells are cycling between active and inactive states, it may be that the longer time to induce cell death with G418 is necessary to give the cells the opportunity to produce neomycin phosphotransferase, the more rapid toxicity of puromycin may kill cells when the replicon is inactive.

If the replicon-harboring cells are only transiently exhibiting RNA replication, this system may be unsuited for evolution of resistance studies, as the replicons will not have the opportunity to acquire mutations and persist over time under selection; nevertheless, our approach provides a powerful, convenient and reproducible system for library screening and studies of putative antivirals. Moreover, reproducibility will be enhanced by continuous re-initiation of replicon expression from the DNA, such that the replicon will not deviate from the cloned sequence over time; in autonomously replicating RNA cell lines, replicons are often seen to undergo culture adaptation (for example (64, 65)). The stability of these DNA-based replicon-harboring cell lines could be of particular value when it is necessary to be able to compare potencies of compounds over large numbers of experiments.

Finally, to expand the utility of the replicons in the study of SARS-CoV-2 replication, we complemented replicon expression with expression of structural proteins, as has been employed in other RNA virus replicon systems (66) including SARS-CoV-2 (41, 43, 45, 46), and were able to demonstrate transmission of SARS-CoV-2 particles bearing S (of either SARS-CoV or SARS-CoV-2) or VSV-G. Reporter gene expression was shown to be dependent on receptor binding and replication, making this a viable approach to study effects on particle assembly and release, and binding and fusion to target cells. Introduction of these replicons with cells expressing structural proteins *in trans* may permit viral spread and thus passaging, as seen in other SARS-CoV-2 replicon systems (41, 45).

In conclusion, the replicon-based systems described here provide tools to examine all facets of the SARS-CoV-2 replication cycle, from cell entry, through protein expression and genome replication, to particle assembly, and can be applied to the diverse range of existing and emerging virus variants. In addition to the numerous applications to basic research, the production of genetically stable, cDNA-based, replicon-harboring cell lines has great potential value for the identification and evaluation of antivirals. The use of integrated cDNA-based replicons may also represent a viable strategy for the production of stable cell lines based on RNA virus replicons that do not readily establish persistent RNA-based replicon-harboring cell lines.

MATERIALS AND METHODS

Cells and viruses

VeroE6 (ATCC) are derived from African green monkey kidney cells and lack the genes encoding type I interferons (67, 68). Huh-7.5 (provided by Charles Rice) are derived from human hepatoma cells. Huh7.5-hAT cells (provided by Gregory Melikian and Mariana Marin), have been modified to stably express human ACE2 and human TMPRSS2, to enhance infection by SARS-CoV-2. A549 (ATCC) are derived from human adenocarcinoma cells. Human embryonic kidney (HEK) 293T cells stably express the SV40 large T antigen, are resistant to neomycin, and were selected for their high transfectability (ATCC). 293T-hAT cells (provided by Bruce Torbett) have been modified to stably express human ACE2 and human TMPRSS2, to permit infection by SARS-CoV-2. Baby hamster kidney (BHK)-21 are a popular substrate for viral growth and may have defects in IFN production and response to IFN (69, 70). These cells were all cultured in humidified conditions at 37 °C in 5% CO₂ in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, non-essential amino acids (NEAA), and 100 U/ml penicillin and 100 µg/ml streptomycin.

Chinese hamster ovary (CHO)-K1 cells (ATCC) are a clonal derivative of the parental CHO cell line and were cultured in humidified conditions at 37 °C in 5% CO₂ in F12 medium supplemented with 10% FBS, 2 mM L-glutamine, and 100 U/ml penicillin and 100 µg/ml streptomycin.

Caco2 cells (ATCC) are a heterogeneous population derived from human colorectal adenocarcinoma and can reflect a wide variety of cell types and properties found in primary tissue. Calu3 cells (ATCC) are a heterogeneous population derived from human lung adenocarcinoma tissue. Both Caco2 and Calu3 cells were cultured in humidified conditions at 37 °C in 5% CO₂ in Eagle's minimum essential medium (EMEM) supplemented with 10% FBS, 2 mM L-glutamine, NEAA, and 100 U/ml penicillin and 100 µg/ml streptomycin.

SARS-CoV-2 strains 2019-nCoV/USA_WA1/2020 and SARS2 hCoV-19/England/204820464/2020 (B.1.1.7) were from BEI Resources and represent the parental and alpha lineages of SARS-CoV-2.

Plasmids, antivirals and chemicals

Plasmids pLVX-EF1a-IRES-Puro SARS-CoV-2 E_NR-52967 and pLVX-EF1a-IRES-Puro SARS-CoV-2 M_NR-52968 (BEI) were gifts from Nevan Krogan (University of California, San Francisco) (71). For our purposes, the E and M coding regions of each plasmid were amplified by PCR, without the STREP tags, and re-

cloned into the vector using the NEBuilder kit (New England Biolabs) following the manufacturer's instructions. SARS-S in pCAGGS was a gift from Paul Bates (University of Pennsylvania) (72). SARS-CoV-2 S was synthesized (Genscript) and cloned into pcDNA3.1 between two PmeI sites using NEBuilder. The plasmid sequence was confirmed by Sanger sequencing. The replicons were cloned into pBeloBAC11 (NEB) (73). The compounds RDV (#30354), EIDD-1931 (#9002958), EIDD-2801/molnupiravir (#29586), GC-376 (#31469), ruxolitinib (#11609), and sodium butyrate (#13121) were purchased from Cayman Chemicals. A chimeric neutralizing antibody specific against SARS-CoV-2 S protein receptor binding domain (NR-55410) was provided by ACROBiosystems through BEI resources.

Construction of the SARS-CoV-2 subgenomic replicon (SARS-2R)

DNA fragments of SARS-CoV-2 replicon were either synthesized from Integrated DNA Technologies Inc or amplified by reverse transcription and PCR (RT-PCR) with viral RNA template that was extracted from the supernatants of SARS-CoV-2-infected Vero cells (SARS-CoV strain 2019-nCoV/USA_WA1/2020 (WA1). RT was performed by using the SuperScript® III First-Strand Synthesis System (ThermoFisher Scientific, Catalogue number 18080051) with gene specific primers (SEM296 5'-ctttaattaactgcttcaacc-3', SEM297 5'-tagtgcaacaggactaagctc-3', SEM298 5'-tgaagtctgtgaattgcaaag-3', SEM299 5'-accagtgattaccttactac-3', SEM300 5'-gttacagttccaattgtgaag-3') and oligo dT primer. Multi-step cloning strategy was used, whereby the fragments named SARS-CoV-2/1 to SARS-CoV-2/9 were sequentially cloned into pBeloBAC11 vector to generate pBAC-SARS-CoV-2-REP. Insertions were performed using the NEBuilder kit following the manufacturer's instructions. The genetic structure of the replicon and the position of relevant restriction enzyme sites are shown at the ends of each fragment. F9 represents the region of the reporter genes.

The sequences of the SARS-2R replicons were confirmed by both Sanger and deep sequencing (initial WT constructs), and subsequent mutations were confirmed by Sanger sequencing the relevant regions.

T7 transcription and RNA electroporation

The DNA template for T7 transcription was prepared by linearizing the T7 replicon plasmid (#453, Supplemental Table I) with the restriction enzyme SacII (NEB), followed by protease K treatment, phenol/chloroform extraction and ethanol precipitation. Replicon RNA was *in vitro* transcribed with the mMESSAGE mMACHINE T7 Transcription Kit (ThermoFisher Scientific) according to the manufacturer's instructions. An 80 µl reaction was set up by adding 8 µg linearized DNA template and 12 µl GTP (cap

analog-to-GTP ratio of 1:1). The reaction mix was incubated at 32 °C for 12 h. Following transcription, template DNA was removed with Turbo DNase, and RNA was recovered with phenol/chloroform extraction and isopropanol precipitation as suggested by the manufacturer. A second transcript coding for SARS-CoV-2 nucleocapsid protein N was *in vitro* transcribed from a PCR product (forward 5'-TACTGTAATACGACTCACTATAGGatgtctgataatggaccccaaaatc-3' [T7 promoter in uppercase] and reverse 5'-TTtaggcctgagttgagtcagcac-3' primers) using the mMESSAGE mMACHINE T7 Transcription Kit. A 20 µl reaction was set up by adding 0.2 µg of N PCR product and 1 µl GTP (cap analog-to-GTP ratio of 2:1). The reaction was incubated at 37 °C for 4 h. N mRNA was purified with RNeasy mini kit (Qiagen).

BHK-21 and 293T cells were trypsinized and washed twice with DPBS (Sigma-Aldrich). BHK-21 cells were adjusted to 1×10^7 cells/ml and 293T cells were adjusted to 5×10^6 cells/ml. For each electroporation, 250 µl cells were pelleted and resuspended in 250 µl of Ingenio electroporation solution (Mirus). For each electroporation, 2.5 µg of each replicon RNA and N mRNA were mixed with cells and transferred to a 0.4 cm electroporation cuvette (pre-chilled on ice). Cells were pulsed once at 280 V for BHK-21 cells and 250 V for 293T cells with Ingenio EZporator MIR51000 electroporation system in low voltage (LV) mode (150 Ω internal resistance and 1050 µF capacitance). After 5 minutes recovery at room temperature, the electroporated cells were transferred to a 10 cm dish or seeded into a 96-well plate. Nano luciferase assays were performed 48 h post electroporation.

Comparison of replicon fitness by transient transfection

Cells were seeded in 24-well plates and incubated until approximately 80 percent confluent. Then cells were transfected with either mock (no replicon) or 0.25 µg replicon plasmid and 0.025 µg N, ORF3b, ORF6 expression plasmids with jetPRIME transfection reagent (Polyplus). In all cases, the amount of SARS-2R nucleic acid transfected was quantified by both agarose gel electrophoresis with ethidium bromide staining and quantification of the absorbance at 260 nm and 280 nm using a NanoDrop spectrophotometer (ThermoFisher Scientific). Nano luciferase activity was assayed using the Nano-Glo Luciferase Assay System (Promega) following manufacturer's instructions. The luciferase signal was measured using a GloMax Navigator Microplate Luminometer (Promega).

Determination of Replicon EC₅₀ and EC₉₀ values

BHK21 cells seeded in 6-well plate were transfected with SARS-2R using jetPRIME transfection reagent (Polyplus transfection). At 16 h post transfection, cells were trypsinized then seeded into 96- or 384-well

plate and treated with serial diluted compounds. Stable cells were seeded directly and treated with serial diluted compounds. Nano luciferase assays were performed 48 hours post treatment. Dose response curves were calculated with Prism software.

Generation of cells that carry SARS-2R replicon

BHK-21 cells were seeded into a 6-well plate, then transfected with replicon SARS-2R_NG_Neo^R_NL using jetPRIME transfection reagent following the manufacturer's instructions. The following day, cells were trypsinized and transferred into a 10 cm dish. After a further 24 h incubation, G418 was added at 1 mg/ml and cells were maintained until distinct colonies formed. Individual colonies were picked and transferred to a 24-well plate. These clones were expanded until near confluency, then NLuc activity was assayed to confirm the presence of active replicon replication. Clones that exhibited a robust NLuc signal were trypsinized then seeded into two separate wells, one treated with 1 μ M RDV to inhibit replicon replication. Clones that exhibited a robust NLuc signal that could be inhibited with RDV were expanded for future studies.

Flow cytometry and subsequent imaging

BHK-SARS-2R_GFP_NeoR_NL cells were trypsinized and washed twice with DPBS (Sigma-Aldrich) and once with sort buffer (PBS supplemented with 0.3 % BSA, 2 mM EDTA, 25 mM HEPES pH 7.0). Cells were adjusted to $1-2 \times 10^7$ cells/ml in sort buffer. GFP+ and GFP- cell sorting was carried out using a BD FACS Aria II SORP Cell Sorter (Pediatric/Winship Flow Cytometry Core, Emory University). After sorting, GFP+ and GFP- cells were seeded into 96-wells at 2500-5000 cells/well. Cells were stained with Hoechst 33342 and counted for GFP+ and total cells with Cytation 5 high-content live-cell imaging system (Biotek) using a 4x objective.

Live cell imaging of replicon harboring cell lines following modulation of cellular transcription

Cells were seeded into 96-well plates at 10,000 cells per well. After 24 h, culture media were removed and replaced with media supplemented with ruxolitinib suppress IFN signaling, sodium butyrate to enhance transcription, and/or RDV to suppress SARS-CoV-2 replication. GFP-positive cells were imaged on a Cytation 5 high-content live-cell imaging system (Biotek) using a 4x objective at 37 °C in 5% CO₂ over 48 to 72 h. Images were captured as a 5x4 matrix and GFP positive cells were enumerated using Gen5 software (Biotek).

qPCR to determine levels of SARS-CoV-2 nucleic acid

RNA and DNA was harvested from the BHK-SARS-2R_GFP_Neo^R_NL cell line using the RNeasy mini kit (Qiagen) and the QIAamp genomic DNA mini kit (Qiagen), respectively. RNA was treated with DNase I (Qiagen) before reverse transcription. Reverse transcription was performed by using the SuperScript[®] III First-Strand Synthesis System (ThermoFisher Scientific) with a gene specific primer 5'-tgaagtctgtgaattgcaaag-3'. qPCR was performed with QuantStudio 3 and Absolute qPCR SYBR Green Mix (Thermo Fisher Scientific) using primers SEM397 5'-cttatgattgaacggttcgtgtc-3' and SEM398 5'-cagaatacatgtctaactgtgtcc-3'. SARS-CoV-2 nucleic acid copy numbers were derived from a calibration curve comprising six 10-fold dilutions of plasmid DNA for SARS-2R_GFP_Neo^R_NL. Final values were averaged from two independent experiments and shown with 95% confidence intervals.

Production of SARS-CoV-2 stocks

SARS-CoV-2 stocks were produced by infection of VeroE6 with SARS-CoV strain 2019-nCoV/USA_WA1/2020 or SARS2 hCoV-19/England/204820464/2020 (B.1.1.7). Media were harvested after 48 hours or when cytopathic effect was observed. To titer viral stocks, VeroE6 cells were seeded in a 96-well plate at 20,000 cells per well. After 24 h, infections were performed with serially diluted viral stocks. Cells were fixed 6 hours post infection (i.e., long enough for expression of viral proteins but short enough that no spread will have occurred) and stained for SARS-CoV-2 N protein to identify infected cells. Infected and total cells were determined by high content microscopy, virus titer was calculated as the number of infected cells per volume of virus stock added to cells.

Determination of SARS-CoV-2 EC₅₀ values

Calu3 cells were seeded in a 96-well plate at 30,000 cells per well and infected when at least 80% confluent. Prior to infection, medium was replaced with fresh medium and supplemented with serially diluted compounds. Duplicate wells for each condition were infected at an MOI of 0.01, fixed 48 h post infection and stained for N protein expression. The number of infected cells at each compound concentration was determined by high content microscopy and dose response curves were plotted and EC₅₀s calculated with Prism software.

Immunofluorescent staining

SARS-CoV-2 infected cells were fixed in 96-well plates with 4% paraformaldehyde in phosphate buffered saline (PBS) for 30 min at room temperature, then incubated in PBS supplemented with 0.1% Triton X-100 for 5 min at room temperature, followed by incubation in blocking buffer (5% FBS in PBS) for 1 h at room temperature. Rabbit monoclonal anti-N antibody (Sino Biologicals #40143-R001) was diluted 1:5,000 in 0.1% Tween-20 in PBS (PBS-T), and incubated on samples overnight at 4 °C. Samples were washed twice in PBS-T, then incubated in secondary goat anti-rabbit Alexa Fluor 647 (Invitrogen #A-21244) diluted 1:2,000 and Hoechst-33342 (ThermoFisher, MA, USA) at 0.5 µg/ml in PBS-T, for 1 h at room temperature. Samples were washed four times in PBS-T. Imaging was performed using a Cytation 5 multimode imaging system with Gen 5 software (Biotek).

Preparation of VLPs

293T cells were seeded into a 6-well plate at 1.2×10^6 cells/well then incubated at 37 °C for 24 h. Each well was transfected with 1 µg replicon SARS-2R_GFP_NeoR_NL, and 0.25 µg each of N, E, and M expression vectors, and 0.25 µg of expression vectors for one of SARS-CoV S, SARS-CoV-2 S, VSV-G or an empty vector, with 4 µl jetPRIME transfection reagent (Polyplus). VLPs were collected 48 h post transfection and passed through a 0.45 µm filter. A 96-well plate was treated with 20 µg/ml poly-D-Lysine (Sigma-Aldrich) for 1h at room temperature and washed twice with 1 x DPBS (Sigma-Aldrich). Target cells were seeded at 4×10^4 cells/well (293T, 293T-hAT) or 2×10^4 cells/well (Huh-7.5, Huh7.5-hAT) and incubated at 37 °C for 24 h. Target cells were infected with 50 µl VLPs per well. For antibody treatment, VLPs were mixed with 2.5 µg/ml neutralizing antibody (BEI NR-55410, provided by ACROBiosystem, cat # SPD-M128) and incubated at 37 °C for 1 h before adding to the target cells. Cells were washed 3 times with PBS at 24 h post infection, then incubated in DMEM for a further 24 h. Nano luciferase assays were performed 48 h post infection.

Calculation of Z'

Cells were seeded in a 6-well plate then transfected with SARS-2R and treated with DMSO or RDV. After 48 h, the NLuc activity in the media was measured for 3 replicate samples per condition. The mean (μ) and standard deviation (σ) were calculated for each treatment condition. Z' was calculated as $1 - [3\sigma \text{ DMSO} + 3\sigma \text{ RDV}] / [\mu \text{ DMSO} - \mu \text{ RDV}]$; an excellent assay should have $Z' > 0.5$, indicating a wide range

between positive and negative controls, combined with small standard deviations. A theoretically perfect assay would have $Z' = 1$.

Statistics

Data were tabulated and graphs plotted using Excel (Microsoft) or Prism (Graphpad). Statistical tests were performed using Prism.

ACKNOWLEDGEMENTS

This research was supported in part by the Nahmias-Schinazi Chair fund at Emory University (SGS). The following reagents were obtained through BEI Resources, NIAID, NIH: SARS-CoV-2 strains 2019-nCoV/USA_WA1/2020 and SARS2 hCoV-19/England/204820464/2020 (B.1.1.7); monoclonal Anti-SARS-Related Coronavirus 2 Spike Glycoprotein Receptor Binding Domain (RBD), Chimeric Potent Neutralizing Antibody (produced in vitro), NR-55410. We wish to thank Nevan Krogan for plasmids pLVX-EF1a-IRES-Puro SARS-CoV-2 E_NR-52967 and pLVX-EF1a-IRES-Puro SARS-CoV-2 M_NR-52968 and Luis Enjuanes for the pBeloBAC11 plasmid. Also Raymond F. Schinazi and Keivan Zandi, for the stock of the WA1 strain and to Ann Chahroudi and Nils Schoof for the stock of B.1.1.7 strain. We also thank Charles M. Rice (Rockefeller University), for the Huh7.5 cells, Gregory Melikian and Mariana Marin (Emory University) for the Huh7.5-hAT cells, Bruce E. Torbett (University of Washington) for the 293T-hAT cell, and Eleftherios Michailidis and Raymond F. Schinazi for useful discussions. We acknowledge the Pediatric/Winship Flow Cytometry Core, Emory University and its personnel for help with use of the BD FACS Aria II SORP Cell Sorter. Finally, we are grateful to Jindi Lan (deceased) for his steadfast support of Shuiyun Lan and family, enabling this research to continue during the COVID-19 pandemic and shutdowns.

REFERENCES

1. Worldometers.info. 2021. COVID-19 CORONAVIRUS PANDEMIC. <https://www.worldometers.info/coronavirus>. Accessed
2. Fu L, Ye F, Feng Y, Yu F, Wang Q, Wu Y, Zhao C, Sun H, Huang B, Niu P. 2020. Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease. *Nature communications* 11:1-8.
3. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. 2020. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 395:497-506.
4. Corman VM, Muth D, Niemeyer D, Drosten C. 2018. Hosts and sources of endemic human coronaviruses. *Advances in virus research* 100:163-188.
5. Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, Emery S, Tong S, Urbani C, Comer JA, Lim W, Rollin PE, Dowell SF, Ling AE, Humphrey CD, Shieh WJ, Guarner J, Paddock CD, Rota P, Fields B, DeRisi J, Yang JY, Cox N, Hughes JM, LeDuc JW, Bellini WJ, Anderson LJ, Group SW. 2003. A novel coronavirus associated with severe acute respiratory syndrome. *N Engl J Med* 348:1953-66.
6. Kuiken T, Fouchier RA, Schutten M, Rimmelzwaan GF, van Amerongen G, van Riel D, Laman JD, de Jong T, van Doornum G, Lim W, Ling AE, Chan PK, Tam JS, Zambon MC, Gopal R, Drosten C, van der Werf S, Escriou N, Manuguerra JC, Stohr K, Peiris JS, Osterhaus AD. 2003. Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. *Lancet* 362:263-70.
7. WHO. 2015. Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003.
8. de Groot RJ, Baker SC, Baric RS, Brown CS, Drosten C, Enjuanes L, Fouchier RA, Galiano M, Gorbalenya AE, Memish ZA, Perlman S, Poon LL, Snijder EJ, Stephens GM, Woo PC, Zaki AM, Zambon M, Ziebuhr J. 2013. Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group. *J Virol* 87:7790-2.
9. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, Hu Y, Tao ZW, Tian JH, Pei YY, Yuan ML, Zhang YL, Dai FH, Liu Y, Wang QM, Zheng JJ, Xu L, Holmes EC, Zhang YZ. 2020. A new coronavirus associated with human respiratory disease in China. *Nature* 579:265-269.
10. Craven J. 26 February 2021 2021. COVID-19 vaccine tracker.
11. Creech CB, Walker SC, Samuels RJ. 2021. SARS-CoV-2 vaccines. *Jama* 325:1318-1320.
12. Feinmann J. 2021. Covid-19: global vaccine production is a mess and shortages are down to more than just hoarding. *BMJ* 375:n2375.
13. Aschwanden C. 2021. Five reasons why COVID herd immunity is probably impossible. *Nature*:520-522.
14. Goldberg Y, Mandel M, Bar-On YM, Bodenheimer O, Freedman L, Haas EJ, Milo R, Alroy-Preis S, Ash N, Huppert A. 2021. Waning immunity after the BNT162b2 vaccine in Israel. *New England Journal of Medicine* 385:e85.
15. Li J, Lai S, Gao GF, Shi W. 2021. The emergence, genomic diversity and global spread of SARS-CoV-2. *Nature*:1-11.
16. CDC. 12/01/2021 2021. SARS-CoV-2 Variant Classifications and Definitions. <https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-classifications.html>. Accessed

17. Alexander A, Brum M, Crow E. 2021. Efficacy and safety of remdesivir for the treatment of severe acute respiratory syndrome due to coronavirus 19: systematic review and meta-analysis.
18. Trøseid M, Hites M, Barratt-Due A, Ader F, Yazdanpanah Y. 2021. Assessing the evidence on remdesivir. *The Lancet Infectious Diseases* 21:1630-1631.
19. Ader F, Bouscambert-Duchamp M, Hites M, Peiffer-Smadja N, Poissy J, Belhadi D, Diallo A, Lê M-P, Peytavin G, Staub T. 2021. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. *The Lancet Infectious Diseases*.
20. Sheahan TP, Sims AC, Zhou S, Graham RL, Pruijssers AJ, Agostini ML, Leist SR, Schafer A, Dinnon KH, 3rd, Stevens LJ, Chappell JD, Lu X, Hughes TM, George AS, Hill CS, Montgomery SA, Brown AJ, Bluemling GR, Natchus MG, Saindane M, Kolykhalov AA, Painter G, Harcourt J, Tamin A, Thornburg NJ, Swanstrom R, Denison MR, Baric RS. 2020. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. *Sci Transl Med* 12.
21. Jayk Bernal A, Gomes da Silva MM, Musungaie DB, Kovalchuk E, Gonzalez A, Delos Reyes V, Martín-Quirós A, Caraco Y, Williams-Diaz A, Brown ML. 2021. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. *New England Journal of Medicine*.
22. Merck. 2021. Merck and Ridgeback Biotherapeutics Provide Update on Results from MOVE-OUT Study of Molnupiravir, an Investigational Oral Antiviral Medicine, in At Risk Adults With Mild-to-Moderate COVID-19.
23. Agbowuro AA, Huston WM, Gamble AB, Tyndall JDA. 2018. Proteases and protease inhibitors in infectious diseases. *Med Res Rev* 38:1295-1331.
24. Zhang Y, Song W, Chen S, Yuan Z, Yi Z. 2021. A bacterial artificial chromosome (BAC)-vectored noninfectious replicon of SARS-CoV-2. *Antiviral Research* 185:104974.
25. Chen CC, Yu X, Kuo CJ, Min J, Chen S, Ma L, Liu K, Guo RT. 2021. Overview of antiviral drug candidates targeting coronaviral 3C-like main proteases. *FEBS J* doi:10.1111/febs.15696.
26. He J, Hu L, Huang X, Wang C, Zhang Z, Wang Y, Zhang D, Ye W. 2020. Potential of coronavirus 3C-like protease inhibitors for the development of new anti-SARS-CoV-2 drugs: Insights from structures of protease and inhibitors. *International journal of antimicrobial agents* 56:106055.
27. Ma C, Sacco MD, Hurst B, Townsend JA, Hu Y, Szeto T, Zhang X, Tarbet B, Marty MT, Chen Y. 2020. Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease. *Cell research* 30:678-692.
28. Rathnayake AD, Zheng J, Kim Y, Perera KD, Mackin S, Meyerholz DK, Kashipathy MM, Battaile KP, Lovell S, Perlman S. 2020. 3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice. *Science translational medicine* 12.
29. Boras B, Jones RM, Anson BJ, Arenson D, Aschenbrenner L, Bakowski MA, Beutler N, Binder J, Chen E, Eng H. 2021. Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19. *Nature Communications* 12:1-17.
30. Owen DR, Allerton CM, Anderson AS, Aschenbrenner L, Avery M, Berritt S, Boras B, Cardin RD, Carlo A, Coffman KJ. 2021. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. *Science*:eabl4784.
31. Administration USFaD. 2021. Coronavirus (COVID-19) Update: FDA Authorizes First Oral Antiviral for Treatment of COVID-19, www.fda.gov.
32. Pfizer. 2021. Pfizer's Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% in Interim Analysis of Phase 2/3 EPIC-HR Study.

33. Hou YJ, Okuda K, Edwards CE, Martinez DR, Asakura T, Dinnon III KH, Kato T, Lee RE, Yount BL, Mascenik TM. 2020. SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract. *Cell* 182:429-446. e14.
34. Xie X, Muruato A, Lokugamage KG, Narayanan K, Zhang X, Zou J, Liu J, Schindewolf C, Bopp NE, Aguilar PV. 2020. An infectious cDNA clone of SARS-CoV-2. *Cell host & microbe* 27:841-848. e3.
35. Hannemann H. 2020. Viral replicons as valuable tools for drug discovery. *Drug discovery today* 25:1026-1033.
36. Bartenschlager R. 2005. The hepatitis C virus replicon system: from basic research to clinical application. *Journal of hepatology* 43:210-216.
37. Hertzog T, Scandella E, Schelle B, Ziebuhr J, Siddell SG, Ludewig B, Thiel V. 2004. Rapid identification of coronavirus replicase inhibitors using a selectable replicon RNA. *Journal of General Virology* 85:1717-1725.
38. Gorbalenya AE, Enjuanes L, Ziebuhr J, Snijder EJ. 2006. Nidovirales: evolving the largest RNA virus genome. *Virus Res* 117:17-37.
39. V'kovski P, Kratzel A, Steiner S, Stalder H, Thiel V. 2021. Coronavirus biology and replication: implications for SARS-CoV-2. *Nature Reviews Microbiology* 19:155-170.
40. He X, Quan S, Xu M, Rodriguez S, Goh SL, Wei J, Fridman A, Koeplinger KA, Carroll SS, Grobler JA. 2021. Generation of SARS-CoV-2 reporter replicon for high-throughput antiviral screening and testing. *Proceedings of the National Academy of Sciences* 118.
41. Ju X, Zhu Y, Wang Y, Li J, Zhang J, Gong M, Ren W, Li S, Zhong J, Zhang L. 2021. A novel cell culture system modeling the SARS-CoV-2 life cycle. *PLoS pathogens* 17:e1009439.
42. Kotaki T, Xie X, Shi P-Y, Kameoka M. 2021. A PCR amplicon-based SARS-CoV-2 replicon for antiviral evaluation. *Scientific reports* 11:1-7.
43. Ricardo-Lax I, Luna JM, Thao TTN, Le Pen J, Yu Y, Hoffmann H-H, Schneider WM, Razooky BS, Fernandez-Martinez J, Schmidt F. 2021. Replication and single-cycle delivery of SARS-CoV-2 replicons. *Science*:eabj8430.
44. Zhang Q-Y, Deng C-L, Liu J, Li J-Q, Zhang H-Q, Li N, Zhang Y-N, Li X-D, Zhang B, Xu Y. 2021. SARS-CoV-2 replicon for high-throughput antiviral screening. *Journal of General Virology* 102:001583.
45. Zhang X, Liu Y, Liu J, Bailey AL, Plante KS, Plante JA, Zou J, Xia H, Bopp NE, Aguilar PV. 2021. A trans-complementation system for SARS-CoV-2 recapitulates authentic viral replication without virulence. *Cell* 184:2229-2238. e13.
46. Malicoat J, Manivasagam S, Zuñiga S, Sola I, McCabe D, Rong L, Perlman S, Enjuanes L, Manicassamy B. 2021. Development of a Single-cycle Infectious SARS-CoV-2 Virus Replicon Particle System for use in BSL2 Laboratories. *Journal of Virology*:JVI. 01837-21.
47. Luo Y, Yu F, Zhou M, Liu Y, Xia B, Zhang X, Liu J, Zhang J, Du Y, Li R. 2021. Engineering a reliable and convenient SARS-CoV-2 replicon system for analysis of viral RNA synthesis and screening of antiviral inhibitors. *Mbio* 12:e02754-20.
48. Nguyen HT, Falzarano D, Gerdtts V, Liu Q, Gallagher T. 2021. Construction of a Noninfectious SARS-CoV-2 Replicon for Antiviral-Drug Testing and Gene Function Studies. *Journal of Virology* 95:e00687-21.
49. Szurgot I, Hanke L, Sheward DJ, Vidakovics LP, Murrell B, McInerney GM, Liljeström P. 2021. DNA-launched RNA replicon vaccines induce potent anti-SARS-CoV-2 immune responses in mice. *Scientific Reports* 11:1-13.
50. Wang B, Zhang C, Lei X, Ren L, Zhao Z, Wang J, Huang H. 2021. Construction of Non-infectious SARS-CoV-2 Replicons and Their Application in Drug Evaluation. *Virologica Sinica*:1-11.

51. Jia Z, Yan L, Ren Z, Wu L, Wang J, Guo J, Zheng L, Ming Z, Zhang L, Lou Z, Rao Z. 2019. Delicate structural coordination of the Severe Acute Respiratory Syndrome coronavirus Nsp13 upon ATP hydrolysis. *Nucleic Acids Res* 47:6538-6550.
52. Eckerle LD, Lu X, Sperry SM, Choi L, Denison MR. 2007. High fidelity of murine hepatitis virus replication is decreased in nsp14 exoribonuclease mutants. *Journal of virology* 81:12135-12144.
53. Eckerle LD, Becker MM, Halpin RA, Li K, Venter E, Lu X, Scherbakova S, Graham RL, Baric RS, Stockwell TB. 2010. Infidelity of SARS-CoV Nsp14-exonuclease mutant virus replication is revealed by complete genome sequencing. *PLoS pathogens* 6:e1000896.
54. Ogando NS, Zevenhoven-Dobbe JC, Meer Yvd, Bredenbeek PJ, Posthuma CC, Snijder EJ, Gallagher T. 2020. The Enzymatic Activity of the nsp14 Exoribonuclease Is Critical for Replication of MERS-CoV and SARS-CoV-2. *Journal of Virology* 94:e01246-20.
55. Pruijssers AJ, George AS, Schafer A, Leist SR, Gralinski LE, Dinno KH, 3rd, Yount BL, Agostini ML, Stevens LJ, Chappell JD, Lu X, Hughes TM, Gully K, Martinez DR, Brown AJ, Graham RL, Perry JK, Du Pont V, Pitts J, Ma B, Babusis D, Murakami E, Feng JY, Bilello JP, Porter DP, Cihlar T, Baric RS, Denison MR, Sheahan TP. 2020. Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice. *Cell Rep* 32:107940.
56. Tao S, Zandi K, Bassit L, Ong YT, Verma K, Liu P, Downs-Bowen JA, McBrayer T, LeCher JC, Kohler JJ. 2021. Comparison of anti-SARS-CoV-2 activity and intracellular metabolism of remdesivir and its parent nucleoside. *Current Research in Pharmacology and Drug Discovery* 2:100045.
57. Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, Smith EC, Case JB, Feng JY, Jordan R. 2018. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. *MBio* 9:e00221-18.
58. Lohmann V. 2019. Hepatitis C virus cell culture models: an encomium on basic research paving the road to therapy development. *Medical microbiology and immunology* 208:3-24.
59. Khan S, Soni S, Veerapu NS. 2020. HCV replicon systems: workhorses of drug discovery and resistance. *Frontiers in Cellular and Infection Microbiology* 10:325.
60. Ge F, Luo Y, Liew PX, Hung E. 2007. Derivation of a novel SARS-coronavirus replicon cell line and its application for anti-SARS drug screening. *Virology* 360:150-158.
61. Liu Y, Liu J, Johnson BA, Xia H, Ku Z, Schindewolf C, Widen SG, An Z, Weaver SC, Menachery VD, Xie X, Shi PY. 2021. Delta spike P681R mutation enhances SARS-CoV-2 fitness over Alpha variant. *bioRxiv* doi:10.1101/2021.08.12.456173.
62. Shi M, Wang L, Fontana P, Vora S, Zhang Y, Fu T-M, Lieberman J, Wu H. 2020. SARS-CoV-2 Nsp1 suppresses host but not viral translation through a bipartite mechanism. *BioRxiv*.
63. Yuan S, Peng L, Park JJ, Hu Y, Devarkar SC, Dong MB, Shen Q, Wu S, Chen S, Lomakin IB. 2020. Nonstructural protein 1 of SARS-CoV-2 is a potent pathogenicity factor redirecting host protein synthesis machinery toward viral RNA. *Molecular cell* 80:1055-1066. e6.
64. Liu S, Chou C-K, Wu WW, Luan B, Wang TT. 2021. Stable Cell Clones Harboring Self-Replicating SARS-CoV-2 RNAs for Drug Screen. *bioRxiv*.
65. Krieger N, Lohmann V, Bartenschlager R. 2001. Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations. *Journal of virology* 75:4614-4624.
66. Lundstrom K. 2016. Replicon RNA viral vectors as vaccines. *Vaccines* 4:39.
67. Emeny JM, Morgan MJ. 1979. Regulation of the interferon system: evidence that Vero cells have a genetic defect in interferon production. *Journal of General Virology* 43:247-252.
68. Mosca J, Pitha P. 1986. Transcriptional and posttranscriptional regulation of exogenous human beta interferon gene in simian cells defective in interferon synthesis. *Molecular and cellular biology* 6:2279-2283.

69. Otsuki K, Maeda J, Yamamoto H, Tsubokura M. 1979. Studies on avian infectious bronchitis virus (IBV). *Archives of Virology* 60:249-255.
70. Habjan M, Penski N, Spiegel M, Weber F. 2008. T7 RNA polymerase-dependent and-independent systems for cDNA-based rescue of Rift Valley fever virus. *Journal of General Virology* 89:2157-2166.
71. Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, White KM, O'Meara MJ, Rezelj VV, Guo JZ, Swaney DL. 2020. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. *Nature* 583:459-468.
72. Simmons G, Reeves JD, Rennekamp AJ, Amberg SM, Piefer AJ, Bates P. 2004. Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry. *Proceedings of the National Academy of Sciences* 101:4240-4245.
73. Almazán F, DeDiego ML, Galán C, Escors D, Álvarez E, Ortego J, Sola I, Zuñiga S, Alonso S, Moreno JL. 2006. Construction of a severe acute respiratory syndrome coronavirus infectious cDNA clone and a replicon to study coronavirus RNA synthesis. *Journal of virology* 80:10900-10906.

Supplemental Tables and Figures

SUPPLEMENTAL TABLE I. List of constructed SARS-2Rs

ID	Background/Mutations	Description/Comments
342	SARS-2R basic replicon	
359	SARS-2R with NLuc-Puro	Addition of a NLuc reporter and Puro for selection of stable cell lines
389	SARS-2R with mNeonGreen-NeoR-NLuc	Addition of NLuc and mNeonGreen reporters and NeoR for selection of stable cell lines
384	SARS-2R with NLuc	Addition of a NLuc reporter only
381	SARS-2R with NLuc-Puro-eGFP	Addition of NLuc and eGFP reporter, the latter fused to Puro for selection of stable cell lines
414	SARS-2R with eGFP-NeoR-NLuc	Addition of eGFP reporter fused to NeoR for selection of stable cell lines, followed by NLuc
453	SARS-2R with eGFP-NeoR-NLuc and T7 promoter	Addition of T7 promoter for in vitro transcription of replicon genomic RNA
362	nsp12 _{D618A} , nsp12 _{D760A}	nsp12 (-): RdRp active site mutations
390	nsp12 _{F480L} , nsp12 _{V557L}	Putative remdesivir-resistance mutations
393	nsp13 _{D374A} , nsp13 _{E375A}	Helicase active site mutation
364	nsp13 _{K345A} , nsp13 _{K347A}	Mutations in nsp13 1A domain β 19- β 20 loop affecting helicase activity
365	nsp14 _{D90A} , nsp14 _{E92A}	nsp14 (-): exonuclease active site mutations
366	nsp15 _{H234A}	nsp15 (-): endoribonuclease active site mutation
367	nsp16 _{E203A}	Nsp16 (-): methyltransferase active site mutation
383	nsp12 _{F480L} , nsp12 _{V557L} , nsp14 _{D90A} , nsp14 _{E92A}	Putative remdesivir-resistance mutations in nsp14 (-) background
SARS-2R with mutations corresponding to Variant of Concern-VOC and Variants Being Monitored-VBM		
456	SARS-2R-CAL20C with mNeonGreen-NeoR-NLuc C241T, C3037T; ORF1a _{J4205V} + ORF1b _{D1183Y} ORF1b _{P314L}	Based on SARS-2R #389; contains mutations corresponding to CAL.20C or epsilon variant (VBM)
457	SARS-2R-B.1.351 with mNeonGreen-NeoR-NLuc C241T, C3037T; ORF1ab _{K1655N} + N _{T205I} ; ORF1b _{P314L}	Based on SARS-2R #389; contains mutations corresponding to B.1.351 or beta variant (VBM)
459	SARS-2R-B.1.1.7 with mNeonGreen-NeoR-NLuc C241T, C3037T; ORF1ab _{T1001I} , A1708D, I2230T, del3675-3677 SGF; ORF1b _{P314L} ; N: D3L, R203K, G204R, S235F	Based on SARS-2R #389; contains mutations corresponding to B.1.1.7 or alpha variant (VBM)
458	SARS-2R-B.1.1.7 with eGFP-NeoR-NLuc C241T, C3037T; ORF1ab _{T1001I} , A1708D, I2230T, del3675-3677 SGF; ORF1b _{P314L} ; N: D3L, R203K, G204R, S235F	Based on SARS-2R #414; contains mutations corresponding to B.1.1.7 or alpha variant (VBM)
476	SARS-2R-B.1.351 with mNeonGreen-NeoR-NLuc C241T, C3037T; ORF1ab _{K1655N} , del3675-3677 SGF; ORF1b _{P314L} ; N _{T205I}	Based on SARS-2R #389; contains mutations corresponding to B.1.351 or beta variant (VBM)
507	SARS-2R-B.1.617.2 with eGFP-NeoR-NLuc C241T, C3037T; ORF1ab _{A1306S} , P2046L, P2287S, V2930L, T3255I, T3646A; ORF1b _{P314L} , G662S, P1000L, A1918V; N _{D63G} , R203M, G215C, D377Y	Based on SARS-2R #414; contains mutations corresponding to B.1.617.2 or delta variant (VOC)

SUPPLEMENTAL TABLE II. Comparison of B.1.1.7 Variant Being Monitored (VBM) to parental WA isolate on antiviral efficiency in Calu3 cells

Virus	Mean EC ₅₀ ± SD (μM)			
	RDV	NHC	EIDD-2801	GC-376
SARS-CoV-2 WA1	0.26±0.088	0.18±0.31	4.1±3.5	1.8±0.42
SARS-CoV-2 B.1.1.7 (Alpha - VBM)	0.5±0.10	0.28±0.34	6.5±2.5	2.1±0.68

For all values N ≥ 2.

No statistically significant differences in EC₅₀ (Dunnett's T3 multiple comparisons test).

Figure S1. SARS-CoV-2 replicon activity in BHK-21 and 293T cells. SARS-2R_NL_Puro^R RNA was transcribed from the BAC using T7 polymerase. BHK-21 or 293T cells were electroporated with SARS-2R_NL_Puro^R RNA then seeded into a 24-well plate and half of the samples were treated with RDV. NLuc activity was determined 48 h post treatment. Data are the average of two independent experiments with standard deviation indicated.

Figure S2. Inhibition of SARS-CoV-2 WT replicon by remdesivir (RDV). 293T cells were transfected with SARS-2R_NL_Puro^R. Cells were trypsinized then seeded into 384-well plate and treated with RDV. NLuc activity was determined 48 h post treatment and dose response curves plotted.

Figure S3. Fitness of SARS-2R-NLuc-Puro^R replicons bearing mutations that modulate resistance to RDV. BHK-21 cells were transfected in 24-well plates with 0.25 µg of SARS-2R replicons carrying the indicated mutations, together with 0.025 µg each of N, ORF3b, and ORF6 expression plasmids. NLuc activity was measured at 48 hpt. Averaged data from 2 independent experiments are shown with standard deviations. P values for pairwise comparisons determined by 2-way ANOVA: ** $p \leq 0.01$; * $p \leq 0.05$.

Mock

Mock+RDV 1 μ M

Ruxo 20 μ M

Ruxo 20 μ M+RDV 1 μ M

Ruxo 20 μ M and NaBtr 5 μ M

Ruxo 20 μ M and NaBtr 5 μ M+RDV 1 μ M

Figure S4. SARS-CoV-2 replicon activity following inhibition of IFN-signalling and derepression of transcription. BHK-SARS-2R_GFP_Neo^R_NL cells were seeded in a 96-well plate at 10,000 per well. After 24 h, media was replaced with media containing the additives indicated. Replicon activity was assessed by counting GFP-positive cells. Images were collected at 4 h intervals using a high content live-cell imaging system. NaBtr, sodium butyrate; Ruxo, ruxolitinib; RDV, remdesivir. Representative data shown from one of two independent experiments. Data presented here are part of the raw data presented in Figure 5.

Figure S5. SARS-CoV-2 replicon activity following inhibition of IFN-signalling and derepression of transcription . BHK-SARS-2R_GFP_Neo^R_NL cells were seeded in a 96-well plate at 10,000 per well. After 24 h, media was replaced with media containing the additives indicated. Replicon activity was assessed by counting GFP-positive cells. Images were collected at 4 h intervals using a high content live-cell imaging system. RDV, remdesivir. Representative data shown from one of two independent experiments.

Figure S6. SARS-CoV-2 replicon activity following inhibition of IFN-signalling and derepression of transcription . BHK-SARS-2R_GFP_Neo^R_NL cells were seeded in a 96-well plate at 10,000 per well. After 24 h, media was replaced with media containing the additives indicated. Replicon activity was assessed by imaging GFP-positive cells after 24 h using a high content live-cell imaging system.

Figure S7. Inhibition of replication activity from BHK-SARS-2R_GFP_Neo^R_NL replicon-expressing stable cell line as measured by multiplex NLuc and GFP markers. The replicon harboring BHK-SARS-2R_GFP_Neo^R_NL cell line was challenged with RDV, NHC, EIDD-2801, and GC-376 in 96-well plates. At 48h post treatment, NLuc activity of supernatants from each well were measured and total GFP positive cells were counted. P1, P2: two biological replicate plates.